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Abstract
Purpose—The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by 
drug exposure and patient genetics. The purpose of this analysis was to expand on a previous 
reported association of CYP2C8*3 and PIPN risk by investigating additional polymorphisms in 
CYP2C8 and in hundreds of other genes potentially relevant to paclitaxel pharmacokinetics.
Methods—Clinical data was collected prospectively in an observational registry of newly 
diagnosed breast cancer patients. Patients treated with paclitaxel-containing regimens were 
genotyped using the Affymetrix DMET™ Plus chip. Patients who carried the CYP2C8*2, *3 or *4 
variant were collapsed into a low-metabolizer CYP2C8 phenotype for association with PIPN. 
Separately, all SNPs that surpassed quality control were assessed individually and as a composite 
of genetic ancestry for associations with PIPN.
Results—412 paclitaxel-treated patients and 564 genetic markers were included in the analysis. 
The risk of PIPN was significantly greater in the CYP2C8 low-metabolizer group (HR=1.722, 
p=0.018), however, the influence of the *2 and *4 SNPs were not independently significant (*2: 
p=0.847, *4: p=0.408). One intronic SNP in ABCG1 (rs492338) surpassed the exploratory 
significance threshold for an association with PIPN in the Caucasian cohort (p=0.0008) but not in 
the non-Caucasian replication group (p=0.54). Substantial genetic variability was observed within 
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self-reported racial groups but this genetic variability was not associated with risk of grade 2+ 
PIPN.
Conclusions—The pharmacogenetic heterogeneity within a cohort of breast cancer patients is 
dramatic, though we did not find evidence that this heterogeneity directly influences the risk of 
PIPN beyond the contribution of CYP2C8*3.
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paclitaxel; pharmacogenetics; breast cancer; chemotherapy-induced peripheral neuropathy; 
ABCG1; Affymetrix DMET™ Plus; CYP2C8; race
Introduction
Paclitaxel is a chemotherapeutic agent frequently used in the treatment of a variety of solid 
tumors including breast, lung, and ovarian cancer. In breast cancer, the sequential addition 
of paclitaxel to standard anthracycline therapy has improved rates of pathological complete 
response in neoadjuvant treatment[1] and overall survival in the adjuvant setting[2, 3]. 
Along with its impressive efficacy, paclitaxel treatment is associated with a variety of severe 
adverse events, including the development of sensory peripheral neuropathy that can 
progress to irreversible loss of manual dexterity and balance[4].
Paclitaxel-induced peripheral neuropathy (PIPN) seems to be multifactorial but drug 
exposure is a primary driver of toxicity development[5–8]. Exposure to paclitaxel is likely 
determined by the activity of the enzymes and transporters involved in its metabolism and 
elimination. Several groups have investigated whether single nucleotide polymorphisms 
(SNPs) within these genes influence drug exposure or PIPN, with inconclusive findings that 
we recently reviewed[9]. Looking across these studies one of the more plausible candidates 
as a risk factor for PIPN is the CYP2C8*3 single nucleotide polymorphism (SNP). CYP2C8 
is responsible for the majority of paclitaxel elimination[10] and the in vivo activity of this 
enzyme correlates with paclitaxel exposure[11]. The CYP2C8*3 SNP (rs10509681, K399R) 
has been reported to decrease paclitaxel metabolism in vitro[12], decrease drug elimination 
in patients(13) and increase paclitaxel efficacy and toxicity[14, 15].
Another factor that has been reported to modify PIPN risk in multiple studies is patient race; 
African-Americans are consistently at greater neuropathy risk than Caucasians[16–18]. It is 
unknown whether this is due to differences in paclitaxel pharmacokinetics or some 
underlying sensitivity to neuropathy. We recently reported corroboration of these 
associations in a cohort of breast cancer patients treated at the UNC Lineberger 
Comprehensive Cancer Center in which CYP2C8*3 and African-American race 
independently increased PIPN risk[16].
In this analysis we sought to expand on our previous work by interrogating nearly 2,000 
SNPs within genes responsible for Drug Metabolism, Elimination, and Transport[19]. We 
hypothesized that a broad pharmacogenetic assessment will identify additional common 
genetic variants that contribute to PIPN risk by first looking within CYP2C8 and then taking 
a discovery approach to individually assess thousands of SNPs that may influence paclitaxel 
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pharmacokinetics. Lastly, we combined all of our genetic data to search for evidence that 
increased PIPN risk in African-Americans is due to germline genetics.
Materials and Methods
Patients and treatments
This cohort, collected from the University of North Carolina Lineberger Comprehensive 
Cancer Center (UNC LCCC) Breast Cancer Database, has been previously described in 
detail(16). This observational registry prospectively collects demographic data including 
treatment and disease characteristics; race was by patient self-report. Toxicity data is 
collected and described prospectively by the treating physician and retrospectively coded 
according to NCI CTC AE V4.0[20] biannually. The primary toxicity endpoint for this 
analysis was grade 2 or higher (grade 2+) neuropathy during paclitaxel treatment. Any 
individual who was enrolled in an IRB approved clinical trial that collected DNA at 
enrollment, was treated with paclitaxel in the neoadjuvant and/or adjuvant setting and 
completed informed consent for genetic studies was eligible for inclusion in this analysis. 
Patients primarily received contemporary neoadjuvant or adjuvant treatment regimens which 
define paclitaxel treatment dose, schedule, and duration. Use of HER2 targeted treatment 
(trastuzumab and/or lapatinib) or agents for neuropathy prevention (glutamine, vitamin B 
complex, or vitamin B6) or treatment (gabapentin or amitriptyline) were at the discretion of 
the treating physician and recorded prospectively in the database. The study protocol was 
approved by the UNC Institutional Review Board.
Genotyping
A 30 mL blood sample was collected from each subject at the time of study enrollment. 
DNA for genotyping was extracted by the UNC Biospecimen Processing Facility and plated 
at 60 ng/uL. Genotyping was carried out blinded to clinical data using the Affymetrix 
DMET™ Plus Chip (Affymetrix Inc., Santa Clara, CA, USA) at Gentris Corp. (Gentris Corp. 
Morrisville, NC) following the manufacturer’s protocol with known genomic DNA controls 
provided by Affymetrix Inc. to monitor inter- and intra-assay performance. Any patient 
sample or assay with successful call rate <95% or <90%, respectively, was excluded from 
analysis. Variants were also excluded if the minor allele frequency was <5% in the entire 
population or if the p-value for the Fisher’s Exact estimate of Hardy-Weinberg proportions 
was <0.05 in either the Caucasian or non-Caucasian cohort (using stratified analysis). 
Genotyping of 359 genetic reference samples from the International Hapmap Project[21] (59 
Caucasian (CEU), 118 African (YRI), 91 Japanese (JPT), and 90 Chinese (CHB)) was also 
performed on the Affymetrix DMET™ Plus Chip as described previously[22].
Statistical Analysis
Combined Analysis of CYP2C8 Low-Activity Variants—In addition to the most 
common CYP2C8 variant (*3) two other somewhat common low-activity variants have been 
reported. The *2 (rs11572103, I269F) and *4 (rs1058930, I264M) SNPs are non-
synonymous variants with diminished metabolic activity[12, 23] found in African (Allele 
Frequency=0.20) and Caucasian (Allele Frequency=0.07) reference populations, 
respectively. Any patient who carried any of these three low-activity variants was combined 
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into a low-metabolizer phenotype. This phenotype was assessed for an association with the 
cumulative dose at the first occurrence of grade 2+ neuropathy using the log-rank test. Any 
patient not experiencing grade 2+ neuropathy was censored at the cumulative dose they were 
administered over the course of therapy. Because the CYP2C8*3 variant had previously 
been analyzed and reported we then used a likelihood ratio test to determine which of the 
three SNPs were significantly contributing to PIPN risk.
DMET Discovery—Of the 1,936 genetic markers on the DMET™ Plus chip, a total of 
1,372 were excluded from analysis. 1,275 markers were excluded for minor allele frequency 
<0.05, which is consistent with previously reported DMET™ marker allele frequencies in 
primarily Caucasian cohorts(24). 30 markers were excluded from the analysis for call rate 
<90% and 67 were eliminated for significant deviation from Hardy-Weinberg proportions. 
Thus after appropriate quality control 564 markers (29.1%) were included in the analysis.
Each individual SNP from the DMET™ Plus Chip that passed quality control was tested for 
an association with the occurrence of grade 2+ neuropathy in the Caucasian patients. This 
analysis was confined to Caucasians because of the heterogeneity in allele frequency across 
racial populations and the known influence of race on neuropathy risk. Neuropathy 
occurrence, in lieu of dose-at-neuropathy, was used in this analysis due to the unacceptable 
lack of robustness of the latter method when applied to the less common (minor allele 
frequency 5–10%) SNPs. Because of the previously reported influence of CYP2C8*3 on 
PIPN in this dataset, the Fisher’s exact test was conditioned on the CYP2C8*3 variant. An 
exploratory significance threshold of α=0.001 was selected for this first-stage discovery 
analysis, which is consistent with prior pharmacogenetic studies utilizing the DMET™ Plus 
Chip[24]. Variants that surpassed the exploratory analysis were tested individually in a log-
rank analysis similar to that performed for the CYP2C8 low-metabolizer analysis. Any 
variant with significant findings in the dose-to-event analysis was then tested in a dose-to-
grade 2+ analysis using the log-rank test in the non-Caucasian subjects (n=124).
Genetic Estimate of Race—All SNPs that passed quality control were included in the 
analysis of population sub-structure and admixture. In order to assess population structure 
from the genetic data, we used two standard approaches, using the reference samples from 
the Hapmap populations (CEU, YRI and JPT/CHB) to help anchor the results. First, we 
calculated principal components using Smartpca in EIGENSOFT[25]. Next, the genetic data 
were processed using STRUCTURE[26] in order to estimate individual ancestry 
corresponding to three major ancestral population clusters—i.e., Caucasian, African and 
Asian. In this sense, STRUCTURE essentially provides an estimation of the proportion of 
the genotypes regions per individual that are derived from each of the major ancestral 
populations. This analysis can reveal admixture that self-reported race does not fully 
capture. The results were labeled according to the ancestral background based on the results 
of the STURCTURE analysis of the reference samples (results not shown). These estimates 
(q scores for each of the three clusters) were then used as an independent variable in a log-
rank test to explore the association between genetically defined race and PIPN risk. All 
inferential statistical analyses were carried out in R Statistical Software, version 2.13.0 (R 
Development Core Team, Vienna, Austria).
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Patient and Genetic Data
After exclusion of one patient whose sample failed genotyping, 288 Caucasian and 124 non-
Caucasian paclitaxel-treated patients were evaluable in these analyses. Demographic data 
including patient and treatment characteristics for these cohorts can be found in Table 1.
Overall 71 patients experienced grade 2+ neuropathy during paclitaxel treatment 
(71/412=18%), which is consistent with other studies of paclitaxel treatment in breast 
cancer[3].
Combined Analysis of CYP2C8 Low-Activity Variants
Any patient who carried a risk allele was collapsed into a CYP2C8 low-metabolizer 
phenotype and compared with all other patients. As hypothesized, the low-metabolizer 
group (n=142) had significantly greater risk of PIPN (HR=1.722, 95% CI 1.10–2.70, 
p=0.018 (Figure 1). Next, a likelihood ratio test was used to determine whether this 
association was driven entirely by the previously published *3 variant. Removing the *3 
variant significantly diminished the performance of the test (p=0.030) while removing either 
of the other SNPs did not (*2: p=0.847, *4: p=0.408) demonstrating that neither of these 
SNPs individually contributed significant explanatory information to the overall model. We 
then performed this analysis in racially stratified subsets but again did not find a significant 
contribution for either SNP (*2: p=0.914 in self-reported blacks, *4: p=0.297 in self-
reported whites). This lack of significance could be due to inadequate power as both the *2 
(HR=1.12) and *4 (HR=1.59) variants’ risk models were trending in the expected direction 
(Supplementary Figures 1a and 1b).
DMET Discovery—Results of the exact tests conditioned on CYP2C8*3 for the 10 
markers with the strongest association with neuropathy incidence are displayed in Table 2, 
including one intronic SNP in ABCG1 (rs492338, uncorrected p=0.0008) that surpassed the 
exploratory significance threshold (α=0.001). A contingency table of neuropathy by 
genotype for the 285 Caucasian patients with genotype calls at this SNP is presented in 
Table 3, exhibiting increased neuropathy risk for the minor (T) allele. The results of the 
secondary analysis using the cumulative dose-at-onset of neuropathy were not meaningfully 
different from the primary findings (HR (per allele)=2.11, 95% CI: 1.36–3.29, p=0.0008, 
Figure 2a). In the attempted cross-race replication in non-Caucasian patients, rs492338 was 
not significantly associated with grade 2+ neuropathy in either the Fisher’s exact (p=0.60) or 
log-rank analysis (p=0.54, Figure 2b).
Genetic Estimate of Population Substructure
Using the results from our STRUCTURE analysis, each patient was categorized by their 
percentage of Caucasian, African, and Asian ancestry. The percentage of African ancestry 
was not associated with the risk of grade 2+ PIPN (p=0.744). We then used these estimates 
to describe the genetic heterogeneity present in this cohort of breast cancer patients. 
Interestingly, the estimate of Caucasian ancestry in self-reported Caucasians ranged from 
very high (maximum=99.7%) to surprisingly low (minimum=16.7%). Similar ranges were 
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found in self-reported African-Americans for regions of the genome directly inherited from 
Caucasian founders (99%-0.1%) and African founders (99.6%-0.5%). Stacked bar plots of 
STRUCTURE output which displays the percentage of Caucasian, African, and Asian 
ancestry, visualized in ascending order of Caucasian genetics, for the cohort stratified by 
self-reported race can be found in Figure 3 and an unstratified plot is included in 
Supplementary Figure 2.
An alternative way to visualize the genetic heterogeneity of a sample of breast cancer 
patients is through principal components analysis. Figure 4 displays the first two principal 
components for our 412 patients and 359 Hapmap reference samples (YRI=118, JPT=91, 
CHB=90, CEU=59). Unlike the reference samples, which tightly cluster by self-reported 
race, our samples again represent a heterogeneous continuum that stretches between the 
reference samples, as expected for a heterogeneous, admixed population.
Discussion
Paclitaxel-induced peripheral neuropathy is known to be dependent on drug exposure. 
Within this patient population we previously demonstrated that patients’ who carry the low-
activity CYP2C8*3 variant are at increased risk of neurotoxicity. We have attempted in the 
present study to identify additional germline variants that influence risk of neuropathy 
through a direct effect on drug pharmacokinetics, beyond that of CYP2C8*3. In order to do 
so we used the Affymetrix DMET™ Plus chip to simultaneously interrogate 1,936 genetic 
variants within 225 genes that encode for the proteins responsible for Drug Metabolism, 
Elimination, and Transport (DMET)[19]. This chip has been previously used to identify 
genetic variants that influence treatment outcomes from various drugs used in cancer and 
other diseases[27–31].
The strategy of combining uncommon SNPs with similar functional effects has been 
successfully used in pharmacogenetics; for example, an association for a common SNP in 
SLCO1B1 with methotrexate pharmacokinetics was extended to other rare variants within 
the gene[32]. We attempted to apply this technique to an analysis of additional low-activity 
non-synonymous CYP2C8 SNPs. Our results for the composite phenotype were consistent 
with the hypothesis; however, due to the low number of each variant genotype we could not 
demonstrate that the addition of either the *2 or *4 SNPs significantly improved our 
findings. This is an inherent limitation of analyses that include rare or uncommon SNPs that 
can only be overcome through the use of larger patient cohorts.
Despite the use of a genotyping platform that interrogates thousands of SNPs in genes 
relevant to drug pharmacokinetics, the only hit that surpassed our exploratory significance 
threshold is located in a gene (ABCG1) not previously identified as a predictor of paclitaxel 
PK[33]. ABCG1 is an intracellular sterol transporter that is primarily recognized for its role 
in regulation of intracellular cholesterol levels, particularly in cholesterol-laden 
macrophages[34]. ABCG1 is also expressed in peripheral neurons[35] where cholesterol is 
converted to pregnenolone, a conversion that is inhibited by paclitaxel in vitro[36]. 
Pregenenolone is then converted to progesterone, 5α-dihydroprogesterone, and 
allopregnanolone, which are referred to as neuroactive steroids[37]. Neuroactive steroids are 
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key regulators of Schwann cell proliferation and myelin formation[38]; processes initiated in 
response to axonal demyelination, a prominent finding in paclitaxel-induced neurotoxicity 
both in vitro[39] and in vivo[40]. Interestingly, co-treatment with neuroactive steroids 
enhances recovery from docetaxel-induced neuropathy in rats[41].
Pharmacogenetic research has been criticized for the proportion of initial findings that 
cannot be replicated. Due to the lack of replication of rs492338 in the non-Caucasian 
patients, in whom this SNP is sufficiently polymorphic, this initial finding should be 
considered a likely false positive unless successful replication is reported in an independent 
patient cohort. Likewise, several groups have reported significant SNP associations with 
paclitaxel exposure or PIPN that we could not reproduce in this cohort, including SNPs in 
CYP3A4[14] and ABCB1[42]. Alternatively, replication could not be attempted of some 
intriguing findings including a model that predicts paclitaxel clearance using the DMET™ 
Plus Chip[33]. We did not attempt validation of this model because we do not have 
paclitaxel clearance data. What is notable from that model is that the 14 SNPs identified are 
found in genes which, like ABCG1, were not previously thought to be directly involved in 
paclitaxel pharmacokinetics. Other SNPs that are not interrogated by the DMET™ Chip, and 
for which replication of previous associations with PIPN could not be attempted, include 
recently identified SNPs in CYP2C8[14] and CYP3A4[43] and virtually everything reported 
in gene or genome-wide studies[44–46].
We also attempted to use a novel approach to elucidate whether the differential PIPN risk 
across race could be explained by variation in candidate genes. We did not find evidence 
that the genetic information included on the DMET™ chip, which focuses mainly on 
enzymes and transporters, explains this risk disparity. This suggests that paclitaxel 
pharmacokinetics is unlikely to be the underlying cause of increased neuropathy in African-
American patients, who may be more sensitive to neuropathy due to comorbidities such as 
diabetes[47] or other unidentified genetic factors. In support of this hypothesis, African-
Americans are known to be at higher neuropathy risk from other etiologies that are unrelated 
to paclitaxel including HIV and diabetes-associated neuropathy[48, 49].
This analysis revealed an underappreciated aspect of medical care, the substantial genetic 
heterogeneity found within patients even within a confined geographic region. A subset of 
patients who self-identify with a given race are genetically quite distinct from that 
population. We have advocated an approach of using global reference populations to bring 
pharmacogenetically-guided rational therapy to countries that lack infrastructure for 
individualized pharmacogenetics[50]. The genetic heterogeneity of breast cancer patients 
within this cohort, as compared to the reference populations, demonstrates the inferiority of 
a race-based stratification system compared with true pharmacogenetic screening. As an 
illustrative example, the CYP2C8*3 allele has not been found in the African or Asian 
reference populations but was found within the relatively small number of self-reported 
African patients within our database (minor allele frequency=0.06).
In conclusion, we have attempted to use the DMET™ Plus Chip to discover SNPs, in 
addition to CYP2C8*3, that modulate risk of PIPN through an effect on drug exposure. The 
independent influence of other less common low-activity variants in CYP2C8 could not be 
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verified, though their direction of effect was consistent with that hypothesized. We 
identified an additional variant in a gene (ABCG1) that is relevant to the regulation of 
endogenous neuroactive steroids which has not been previously investigated in candidate 
SNP association studies of PIPN to our knowledge. The finding could not be replicated in 
the smaller non-Caucasian cohort, suggesting that the effect may be exclusive to Caucasian 
subjects or may represent a false positive. Finally, though we could not find evidence that 
the enhanced risk of PIPN in African-American patients is caused by genetic variation in the 
genes assessed by the DMET™ Plus Chip, we did find dramatic evidence of genetic 
heterogeneity in breast cancer patients. This illustrates the necessity of developing 
infrastructure for clinical genetic testing to guide pharmacogenetic treatment 
individualization for those associations that have demonstrated clinical utility.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Incidence of grade 2+ neuropathy by CYP2C8 metabolizer status. All patients carrying a 
CYP2C8*2, *3 or *4 allele were grouped into a low-metabolizer phenotype. As 
hypothesized, CYP2C8 low-metabolizers had a greater risk of neuropathy (p=0.02).
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Incidence of grade 2+ neuropathy by ABCG1 (rs492338) genotype in Caucasian (n=285) 
(Fig 2A, left) and non-Caucasian (n=124) (Fig 2B, right) patients. The increase in 
neuropathy risk for patients carrying rs492338 discovered in Caucasians (p=0.0008) could 
not be replicated in non-Caucasians (p=0.542), suggesting that if the original association is 
true it may be race-specific.
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Stacked bar plots displaying the percentage of Caucasian (green), African (blue), and Asian 
(red) ancestry, visualized in ascending order of Caucasian genetics stratified by self-reported 
race. Race was verified by other documentation within the medical record for all patients 
whose genetic ancestry was <80% concordant with their self-reported race. The self-
reported white patients are genetically predominantly Caucasian; however, some patients 
have substantial African and/or Asian genetic ancestry. Similarly, the self-reported black 
patients exist on a continuum between almost entirely genetically African and almost 
entirely genetically Caucasian. Interestingly, Asians are the most genetically homogeneous 
of the racial groups.
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Plot of first two principal components for 412 breast cancer patients and 359 reference 
samples (YRI=118, JPT=91, CHB=90, CEU=59). The reference samples tightly cluster by 
race due to genetic homogeneity. The patient samples tend to cluster near the corresponding 
reference samples but demonstrate substantially greater genetic heterogeneity, particularly 
for the self-reported black patients who represent a continuum between the African and 
Caucasian reference populations.
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Table 1




African-American 0 107 (86%)





Yes 49 (17%) 28 (23%)
No 239 (83%) 97 (78%)
Diabetes Diagnosis
Yes 24 (8%) 24 (19%)
No 264 (92%) 100 (81%)
Paclitaxel Schedule & Dose
80–90 mg/m2 Weekly 91 (32%) 40 (32%)
175 mg/m2 Every 2 weeks 163 (57%) 73 (59%)
175 mg/m2 Every 3 weeks 34 (12%) 11 (9%)
Supplemental Neuropathy Therapy
Glutamine 84 (29%) 28 (23%)
Gabapentin 7 (2%) 8 (6%)
Amitriptyline 8 (3%) 1 (1%)
Vitamin B6 5 (2%) 2 (2%)
Vitamin B Complex 1 (<1%) 1 (1%)







Treatment Prior to Paclitaxel
AC (Doxorubicin/Cyclophosphamide) 216 (75%) 100 (81%)
AC + Bevacizumab 2 (1%) 0
A (Doxorubicin) 2 (1%) 0
AC + Docetaxel 0 1 (1%)
Treatment Concurrent to Paclitaxel
Trastuzumab 46 (16%) 25 (20%)
Bevacizumab 4 (1%) 5 (4%)
Carboplatin 1 (<1%) 1 (1%)
Carboplatin + Bevacizumab 1 (<1%) 2 (2%)
Trastuzumab + Lapatinib 4 (1%) 0
Trastuzumab + Cyclophosphamide 1 (<1%) 0
Treatment Settinga
Neoadjuvant 137 (48%) 52 (42%)
Adjuvant 153 (53%) 73 (59%)
Counts and percentages (in parentheses) are presented for categorical data. Medians and ranges are presented for quantitative data.
a
Two patients in the primary cohort and one in the replication cohort were treated with paclitaxel neoadjuvantly and adjuvantly
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Table 2
Variants with strongest association with grade 2+ peripheral neuropathy occurrence in Caucasian cohort
Rank Gene Variant rsID Fisher’s Exact P-Value Conditioned on CYP2C8*3
1 ABCG1 (intronic) rs492338 0.0008*
2 CYP4A11 (3′UTR) rs11211402 0.0010
3 CYP4B1_14422C>T(R173W) rs4646487 0.0015
4 GSTA5 (intronic) rs4715354 0.0018
5 ABCG1 (intronic) rs3788007 0.0033
6 CBR1 (intronic) rs998383 0.0037
7 ABCC1_94714T>C(V275V) rs246221 0.0039
8 GSTA1 (5′ UTR) rs4715332 0.0049
9 SLC16A1_15385T>A(D490E) rs1049434 0.0056
10 CYP17A1_195G>T(S65S) rs6163 0.0066
*
Surpassed exploratory α=0.001
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Table 3
Neuropathy Occurrence by Genotype for intronic ABCG1 SNP (rs492338) in Caucasian Patients.
Gene Variant Genotype Neuropathy Incidence Odds Ratio Vs. Homozygous Wild-Type
ABCG1
rs492338 [Intronic]
C/C 6/66 (9.1%) -
C/T 23/157 (14.6%) OR= 1.70, 95% CI: (0.63- 5.37)
p=0.38
T/T 20/62 (32.2%) OR= 4.70, 95% CI: (1.64- 15.57)
p=0.002
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